[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649498":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":34,"locations":24,"responsibleParty":42,"collaborators":24,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":24,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":24,"enrollmentInfo":53,"targetDuration":24,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":68,"whyStopped":24,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":24},{"fullName":5,"class":6},"Umoja Biopharma","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"UB-VV500","EXPERIMENTAL","A single dose of UB-VV500 will be administered.",[13],"Genetic: UB-VV500",{"label":15,"type":10,"description":16,"interventionNames":17},"UB-VV500 + rapamycin","A single dose of UB-VV500 will be administered followed by treatment with rapamycin.",[13,18],"Drug: Rapamycin (sirolimus)",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"GENETIC","UB-VV500 is a gene therapy that generates CAR T cells that target both B-cell maturation antigen (BCMA) and G protein-coupled receptor, family C, group 5, member D (GPRC5D) in the body.",[9,15],null,{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":24},"DRUG","Rapamycin (sirolimus)","Rapamycin is a drug approved by the FDA for indications unrelated to cancer.",[15],[31],{"name":32,"affiliation":5,"role":33},"Luke Walker, MD","STUDY_DIRECTOR",[35,39],{"name":32,"role":36,"phone":37,"phoneExt":24,"email":38},"CONTACT","206-227-5056","luke.walker@umoja-biopharma.com",{"name":40,"role":36,"phone":24,"phoneExt":24,"email":41},"Erin Mullane","erin.mullane@umoja-biopharma.com",{"type":43,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100649498","phase-1-a-phase-1-study-of-ub-vv500-with-rapamycin-in-relapsedrefractory-multiple-myeloma-100649498",false,"NCT07735546","A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed\u002FRefractory Multiple Myeloma","A Phase 1, Open-label, Multicenter Study of UB-VV500 With Rapamycin in Relapsed or Refractory Multiple Myeloma","Inclusion Criteria:\n\n1. 18 years or older\n2. Provides voluntary written informed consent\n3. Relapsed or refractory multiple myeloma (MM) following treatment with a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody\n4. Measurable disease following completion of most recent anticancer therapy\n5. No serious concomitant diseases or active\u002Funcontrolled infections\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n7. Adequate organ function\n\nExclusion Criteria:\n\n1. Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome, or primary AL amyloidosis\n2. Solitary plasmacytomas without evidence of systemic disease\n3. Women who are pregnant or breastfeeding\n4. Current isolated central nervous system (CNS) involvement\n5. Prior allogeneic bone marrow transplant, gene therapy, or adoptive cell transfer (except tumor-infiltrating lymphocytes, CAR-NK cells, T-cell receptor \\[TCR\\] fusion constructs, TCR T cells, and CAR T cells)\n6. History of or active human immunodeficiency virus (HIV)\n7. Active or chronic hepatitis B, or active hepatitis C\n8. Systemic immunodeficiency diseases, except for well-controlled Type I diabetes or thyroid disease\n9. Ongoing CNS disease that would preclude neurologic assessment\n10. Uncontrolled angina or other acute heart disease\n11. Currently receiving treatment in another interventional clinical trial.","ALL","18 Years",{"count":54,"type":55},100,"ESTIMATED","INTERVENTIONAL",[58],"PHASE1","This study is a Phase 1 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV500. The study will enroll patients with relapsed\u002Frefractory multiple myeloma.",[61,62],"Multiple Myeloma in Relapse","Multiple Myeloma (MM)",[64,65,66,67],"CAR T","chimeric antigen receptor","BCMA","GPRC5D","NOT_YET_RECRUITING","2026-08-13",{"date":71,"type":72},"2026-08-17","ACTUAL",{"date":74,"type":55},"2026-10-01",{"date":76,"type":55},"2029-12-31",{"name":5,"class":6}]